

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPAL653HXP

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	12	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	17	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	18	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	20	JUL 28	STN Viewer performance improved
NEWS	21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	22	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	24	AUG 15	Caplus currency for Korean patents enhanced
NEWS	25	AUG 25	CA/CAPLUS, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS	26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	27	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	28	SEP 25	CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of

exemplified prophetic substances  
NEWS 29 SEP 26 WPIDS, WPINDEX, and WPIX coverage of Chinese and  
and Korean patents enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:17:07 ON 27 SEP 2008

=> file medline, uspatful, dgene, embase, wpids, hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 15:17:33 ON 27 SEP 2008

FILE 'USPATFULL' ENTERED AT 15:17:33 ON 27 SEP 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 15:17:33 ON 27 SEP 2008  
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'EMBASE' ENTERED AT 15:17:33 ON 27 SEP 2008  
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 15:17:33 ON 27 SEP 2008  
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'HCAPLUS' ENTERED AT 15:17:33 ON 27 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s compound and ester prodrug  
L1 915 COMPOUND AND ESTER PRODRUG

=> s l1 and (salt)  
L2 715 L1 AND (SALT)

=> s compound and (nitrogen protecting group)  
L3 2525 COMPOUND AND (NITROGEN PROTECTING GROUP)

=> s l3 and carboxylic acid protecting group  
3 FILES SEARCHED...  
L4 57 L3 AND CARBOXYLIC ACID PROTECTING GROUP

=> s l4 and (lysyl)  
L5 11 L4 AND (LYSYL)

=> s l5 and l2  
L6 0 L5 AND L2

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 11 USPATFULL on STN

T1 Conjugates and compositions for cellular delivery

AB This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including cholesterol, folate, galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide and human serum albumin (HSA) derived conjugates of biologically active compounds, including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones, nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids, DNazymes, allozymes, antisense, dsRNA, siRNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys and aptamers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:315501 USPATFULL

TITLE: Conjugates and compositions for cellular delivery

INVENTOR(S): Vargeese, Chandra, Broomfield, CO, UNITED STATES

Haeberli, Peter, Berthoud, CO, UNITED STATES

Wang, Weimin, Superior, CO, UNITED STATES

Chen, Tongqian, Longmont, CO, UNITED STATES

PATENT ASSIGNEE(S): Sirna Therapeutics, Inc., Boulder, CO, UNITED STATES  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040249178	A1	20041209
APPLICATION INFO.:	US 2004-780447	A1	20040213 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-427160, filed on 30 Apr 2003, PENDING Continuation-in-part of Ser. No. WO 2002-US15876, filed on 20 May 2002, PENDING Continuation-in-part of Ser. No. WO 2003-US5346, filed on 20 Feb 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2002-US15876	20020520
	WO 2003-US5346	20030220
	WO 2003-US5028	20030220
	US 2001-292217P	20010518 (60)
	US 2001-306883P	20010720 (60)
	US 2001-311865P	20010813 (60)
	US 2002-362016P	20020306 (60)
	US 2002-358580P	20020220 (60)
	US 2002-363124P	20020311 (60)
	US 2002-386782P	20020606 (60)
	US 2002-406784P	20020829 (60)
	US 2002-408378P	20020905 (60)
	US 2002-409293P	20020909 (60)
	US 2003-440129P	20030115 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, 300 S. WACKER DRIVE, 32ND FLOOR, CHICAGO, IL, 60606

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 51 Drawing Page(s)  
LINE COUNT: 5782  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 11 USPATFULL on STN

TI Novel antiangiogenic peptides, polypeptides encoding same and methods for inhibiting angiogenesis  
AB Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:178957 USPATFULL  
TITLE: Novel antiangiogenic peptides, polypeptides encoding same and methods for inhibiting angiogenesis  
INVENTOR(S): Davidson, Donald J., Gurnee, IL, UNITED STATES  
Wang, Jieyi, Gurnee, IL, UNITED STATES  
Gubbins, Earl J., Libertyville, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040138127	A1	20040715
APPLICATION INFO.:	US 2004-753646	A1	20040108 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-924287, filed on 5 Sep 1997, GRANTED, Pat. No. US 6699838 Continuation-in-part of Ser. No. US 1997-851350, filed on 5 May 1997, GRANTED, Pat. No. US 6057122 Continuation-in-part of Ser. No. US 1997-832087, filed on 3 Apr 1997, GRANTED, Pat. No. US 5981484 Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, GRANTED, Pat. No. US 5801146		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008		
NUMBER OF CLAIMS:	68		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Page(s)		
LINE COUNT:	3457		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 11 USPATFULL on STN

TI Conjugates and compositions for cellular delivery  
AB This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including cholesterol, folate, galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide and human serum albumin (HSA) derived conjugates of biologically active compounds, including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones, nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids, DNazymes, allozymes, antisense, dsRNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys and aptamers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:144631 USPATFULL  
TITLE: Conjugates and compositions for cellular delivery  
INVENTOR(S): Vargeese, Chandra, Broomfield, CO, UNITED STATES  
Haeberli, Peter, Berthoud, CO, UNITED STATES  
Wang, Weimin, Superior, CO, UNITED STATES  
Chen, Tongqian, Longmont, CO, UNITED STATES

PATENT ASSIGNEE(S):       Ribozyme Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040110296	A1	20040610
APPLICATION INFO.:	US 2003-427160	A1	20030430 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-US15876, filed on 20 May 2002, PENDING Continuation-in-part of Ser. No. WO 2003-US5346, filed on 20 Feb 2003, PENDING Continuation-in-part of Ser. No. WO 2003-US5028, filed on 20 Feb 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-292217P	20010518 (60)
	US 2001-306883P	20010720 (60)
	US 2001-311865P	20010813 (60)
	US 2002-362016P	20020306 (60)
	US 2002-358580P	20020220 (60)
	US 2002-363124P	20020311 (60)
	US 2002-386782P	20020606 (60)
	US 2002-406784P	20020829 (60)
	US 2002-408378P	20020905 (60)
	US 2002-409293P	20020909 (60)
	US 2003-440129P	20030115 (60)

DOCUMENT TYPE:       Utility  
FILE SEGMENT:       APPLICATION  
LEGAL REPRESENTATIVE: MCDONNELL BOEHNEN HULBERT & BERGHOF LLP, 300 S. WACKER DRIVE, 32ND FLOOR, CHICAGO, IL, 60606

NUMBER OF CLAIMS:     21  
EXEMPLARY CLAIM:     1  
NUMBER OF DRAWINGS:   51 Drawing Page(s)  
LINE COUNT:           5686  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5   ANSWER 4 OF 11 USPATFULL on SIN  
T1   Antiangiogenic peptides  
AB   Mammalian kringle 5 fragments and kringle 5 fusion proteins are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER:     2004:53363 USPATFULL  
TITLE:                Antiangiogenic peptides  
INVENTOR(S):          Davidson, Donald J., Gurnee, IL, United States  
PATENT ASSIGNEE(S):   Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6699838	B1	20040302
APPLICATION INFO.:	US 1997-924287		19970905 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-851350, filed on 5 May 1997, now patented, Pat. No. US 6057122 Continuation-in-part of Ser. No. US 1997-832087, filed on 3 Apr 1997, now patented, Pat. No. US 5981484 Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Low, Christopher S. F.		

ASSISTANT EXAMINER: Robinson, Hope A.  
LEGAL REPRESENTATIVE: Casuto, Dianne, Steele, Gregory W.  
NUMBER OF CLAIMS: 4  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)  
LINE COUNT: 3178  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 11 USPATFULL on STN

TI Conjugates and compositions for cellular delivery

AB This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide and human serum albumin (HSA) derived conjugates of biologically active compounds, including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones, nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids, DNazymes, allozymes, antisense, dsRNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys and aptamers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:188393 USPATFULL

TITLE: Conjugates and compositions for cellular delivery

INVENTOR(S): Vargeese, Chandra, Thornton, CO, UNITED STATES  
Matulic-Adamic, Jasenka, Boulder, CO, UNITED STATES  
Karpeisky, Alexander, Lafayette, CO, UNITED STATES  
Beigelman, Leonid, Longmont, CO, UNITED STATES  
Blatt, Lawrence, Boulder, CO, UNITED STATES  
Zinnen, Shawn, Denver, CO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030130186	A1	20030710
APPLICATION INFO.:	US 2002-201394	A1	20020722 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-311865P	20010813 (60)
	US 2001-306883P	20010720 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606

NUMBER OF CLAIMS: 40

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 23 Drawing Page(s)

LINE COUNT: 4466

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 11 USPATFULL on STN

TI Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors

AB Modified peptide fragments of plasminogen domain are provided which exhibit anti-angiogenic activity. Compositions containing these peptide fragments and methods of using these compositions to treat angiogenic dependent and associated disorders are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:79063 USPATFULL

TITLE: Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors

INVENTOR(S): Ji, Weidong-Richard, Philadelphia, PA, UNITED STATES  
Meyers, Chester A., Medford, NJ, UNITED STATES  
Natarajan, Seshu I., Hillsborough, NJ, UNITED STATES  
Trail, Pamela A., Madison, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030054988	A1	20030320
APPLICATION INFO.:	US 2001-999457	A1	20011031 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245384P	20001102 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	557	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 11 USPATFULL on SIN  
TI Antiangiogenic peptides and methods for inhibiting angiogenesis  
AB Mammalian kringle 5 fragments are disclosed as a compounds for treating  
angiogenic diseases. Methods and compositions for inhibiting angiogenic  
diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2001:97890 USPATFULL  
TITLE: Antiangiogenic peptides and methods for inhibiting  
angiogenesis  
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States  
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251867	B1	20010626
APPLICATION INFO.:	US 1998-132154		19980811 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-132154, filed on 11 Aug 1998 And Ser. No. US 1997-832087, filed on 3 Apr 1997 Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Hendricks, Keith D.		
ASSISTANT EXAMINER:	Stole, Einar		
LEGAL REPRESENTATIVE:	Steele, Gregory W., Casuto, Dianne		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2101		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 11 USPATFULL on SIN  
TI Antiangiogenic peptides polynucleotides encoding same and methods for  
inhibiting angiogenesis  
AB Mammalian kringle 5 fragments and kringle 5 fusion proteins are  
disclosed as a compounds for treating angiogenic diseases. Methods and  
compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:53906 USPATFULL  
TITLE: Antiangiogenic peptides polynucleotides encoding same  
and methods for inhibiting angiogenesis  
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States  
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6057122		20000502
APPLICATION INFO.:	US 1997-851350		19970505 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-832087, filed on 3 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Stole, Einar		
LEGAL REPRESENTATIVE:	Steele, Gregory W., Casuto, Dianne		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	3215		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 11 USPATFULL on STN

TI Antiangiogenic peptides and methods for inhibiting angiogenesis  
AB Mammalian kringle 5 peptide fragments are disclosed for treating  
angiogenic diseases Methods and compositions for inhibiting angiogenic  
diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:141891 USPATFULL  
TITLE: Antiangiogenic peptides and methods for inhibiting  
angiogenesis  
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States  
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981484		19991109
APPLICATION INFO.:	US 1997-832087		19970403 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Prouty, Rebecca E.		
ASSISTANT EXAMINER:	Stole, Einar		
LEGAL REPRESENTATIVE:	Steele, Gregory W., Casuto, Dianne		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2474		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 11 USPATFULL on STN

TI Antiangiogenic peptides and methods for inhibiting angiogenesis



AB Mammalian kringle 5 fragments are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:132781 USPATFULL  
TITLE: Antiangiogenic peptides and methods for inhibiting angiogenesis  
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States  
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972896		19991026
APPLICATION INFO.:	US 1998-131995		19980811 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-832087, filed on 3 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Stole, Einar		
LEGAL REPRESENTATIVE:	Steele, Gregory W., Casuto, Dianne		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2444		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 11 WPIDS COPYRIGHT 2008 THOMSON REUTERS on STN

TI Novel kringle 5 peptide compound or kringle 5 fusion protein, useful for inhibiting angiogenesis and thus for treating cancer, arthritis, macular degeneration and diabetic retinopathy

AN 2004-552394 [53] WPIDS

CR 1997-558670; 2000-349573; 2004-224006

AB US 20040138127 A1 UPAB: 20050706

NOVELTY - A kringle 5 peptide compound or kringle 5 fusion protein (I) which comprises amino acid residues 1-197 corresponding to sequence comprising amino acids 334-530 of a fully defined human plasminogen molecule (including its kringle 5 region) sequence (S1) of 791 amino acids as given in specification, and 1-12 amino acid residues corresponding to sequence from amino acid position 535-546 of (S1), is new.

DETAILED DESCRIPTION - A compound having the formula:

(a) A-B-C-X-Y (F1) or its salt, ester or prodrug, where A is absent or a nitrogen protecting group; Y is absent or a carboxylic acid protecting group; B is absent or is 1-197 naturally occurring amino acid residues corresponding to sequence from amino acid position 334-530 of (S1); C is R1-R2-R3-R4, where R1 is lysyl; R2 is leucyl or arginyl; R3 is tyrosyl, 3-I-tyrosyl or phenylalanyl; R4 is aspartyl; and X is absent or is 1-12 naturally occurring amino acid residues corresponding to the sequence from amino acid position 535-546 of (S1) and their homologs or analogs; or

(b) A-B1-C1-X1-Y (F2) or its salt, ester or prodrug, where A and Y are as described above; B1 is absent or is 1-176 naturally occurring amino acid residues corresponding to the sequence from amino acid position 334-513 of (S1); C1 is the sequence from 514-523 amino acid position of (S1); and X1 is absent or is 1-10 naturally occurring amino acid residues

corresponding to the sequence from amino acid position 524-533 of (S1) and their homologs or analogs.

The kringle 5 peptide fragment has substantially sequence homology to a plasminogen fragment chosen from human, murine, bovine, Rhesus monkey and porcine plasminogen.

INDEPENDENT CLAIMS are also included for the following:

(1) a composition (C1) comprising a mammalian isolated single- or double-stranded polynucleotide sequence (II) that encodes a kringle 5 peptide fragment or kringle 5 fusion protein having angiogenesis inhibiting activity;

(2) a composition (C2) comprising a kringle 5 peptide fragment or kringle 5 fusion protein and an excipient;

(3) (II) as described above;

(4) a vector (III) comprising (II);

(5) implanting into a human or non-human animal a cell containing a vector, where the vector contains (II) and where the vector is capable of expressing the kringle 5 peptide fragment or kringle 5 fusion protein when present in the cell;

(6) making a kringle 5 peptide fragment involves exposing a mammalian plasminogen to elastase at a ratio of 1:100-1:300 to form a mixture of the plasminogen of the elastase, incubating the mixture, and isolating the kringle 5 from the mixture; and

(7) making a soluble kringle 5 peptide fragment or kringle 5 fusion protein involves isolating a polynucleotide which encodes the kringle 5 peptide fragment, cloning the polynucleotide into an expression vector, transforming the vector into a suitable host cell, and growing the host cell under conditions suitable for the expression of the soluble kringle 5 peptide fragment or kringle 5 fusion protein.

ACTIVITY - Cytostatic; Antiarthritic; Ophthalmological; Antipsoriatic; Antidiabetic; Antirheumatic; Antiinflammatory; Antiatherosclerotic; Dermatological; Vulnerary; Contraceptive.

MECHANISM OF ACTION - Angiogenesis inhibitor; Endothelial cell proliferation inhibitor; Ovulation inhibitor. The effect of kringle 5 peptide fragments on endothelial cell proliferation was determined in vitro using endothelial cell proliferation assay. Kringle 5 peptide fragments were prepared and tested at various concentrations ranging from 100-1000 pm with basic fibroblast growth factor. The kringle 5 peptide fragment was effective at inhibiting bovine capillary (adrenal) endothelial cell (BCE) proliferation in a dose-dependent manner. The concentration of kringle 5 peptide fragment required to reach 50% inhibition (ED50) was determined at about 300 pM. In contrast, the ED50 of kringles 1-4 was shown to be 135 nM. The kringle 3 peptide fragment was least effective at inhibiting BCE cell proliferation (ED50 = 460 nM), followed by the kringle 1 peptide fragment (ED50 = 320 nM), kringle 1-4 peptide fragments (ED50 = 75 nM) and kringles 1-3 peptide fragments was the most effective at inhibiting BCE cell proliferation with an ED50 of 0.3.

USE - (I) (more preferably, human kringle 5 peptide fragment or kringle 5 fusion protein) is useful for treating a disease in a patient in need of antiangiogenesis therapy, preferably for treating cancer, arthritis, macular degeneration and diabetic retinopathy, more preferably cancer, metastatic solid tumors, carcinomas, sarcomas, lymphomas, psoriasis and hemangiomas (claimed). (I) is useful for treating primary and metastatic solid tumors and carcinomas of the breast, colon, rectum, lung, etc., and for prophylaxis of autoimmune diseases such as rheumatoid arthritis, retrolental fibroplasias, abnormal neovascularization conditions of the eye, Osler-Webber syndrome, myocardial angiogenesis; diseases characterized by abnormal stimulation of endothelial cells such as Crohn's disease, atherosclerosis, scleroderma and hypertrophic scars (that is keloids). (I) is also useful as a birth control agent which inhibits ovulation and establishment of the placenta. (I) is useful for preventing

metastasis from tumors. (I) is useful as agonist or antagonist active at kringle 5 binding site, as antigens for developing specific antisera, as peptides for use in diagnostic kits, and as peptides linked to or used in combination with cytotoxic agents for targeted killing of cells that bind kringle 5 peptide fragments. (I) is also useful for isolating kringle 5 receptor. (III) is useful in gene therapy techniques for treating the above mentioned conditions.

ACCESSION NUMBER: 2004-552394 [53] WPIDS  
 CROSS REFERENCE: 1997-558670; 2000-349573; 2004-224006  
 DOC. NO. CPI: C2004-208850 [56]  
 TITLE: Novel kringle 5 peptide compound or kringle 5 fusion protein, useful for inhibiting angiogenesis and thus for treating cancer, arthritis, macular degeneration and diabetic retinopathy  
 DERWENT CLASS: A96; B04; D16  
 INVENTOR: DAVIDSON D J; GUBBINS E J; WANG J  
 PATENT ASSIGNEE: (DAVI-I) DAVIDSON D J; (GUBB-I) GUBBINS E J; (WANG-I) WANG J  
 COUNTRY COUNT: 1

# PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
-----						
US 20040138127	A1	20040715	(200453)*	EN	53[7]	

# APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----			
US 20040138127	A1	CIP of	US 1996-643219 19960503
US 20040138127	A1	CIP of	US 1997-832087 19970403
US 20040138127	A1	CIP of	US 1997-851350 19970505
US 20040138127	A1	Cont of	US 1997-924287 19970905
US 20040138127	A1		US 2004-753646 20040108

# FILING DETAILS:

PATENT NO	KIND	PATENT NO
-----		
US 20040138127	A1	CIP of US 5801146 A
US 20040138127	A1	CIP of US 5981484 A
US 20040138127	A1	CIP of US 6057122 A
US 20040138127	A1	Cont of US 6699838 B

PRIORITY APPLN. INFO: US 2004-753646 20040108  
 US 1996-643219 19960503  
 US 1997-832087 19970403  
 US 1997-851350 19970505  
 US 1997-924287 19970905

=> d his

(FILE 'HOME' ENTERED AT 15:17:07 ON 27 SEP 2008)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, HCAPLUS' ENTERED AT 15:17:33 ON 27 SEP 2008

L1 915 S COMPOUND AND ESTER PRODRUG  
 L2 715 S L1 AND (SALT)  
 L3 2525 S COMPOUND AND (NITROGEN PROTECTING GROUP)

L4 57 S L3 AND CARBOXYLIC ACID PROTECTING GROUP  
L5 11 S L4 AND (LYSYL)  
L6 0 S L5 AND L2

=> s (lysyl-leucyl-tyrosyl-aspartyl)  
L7 6 (LYSYL-LEUCYL-TYROSYL-ASPARTYL)

=> d l7 ti abs ibib tot

L7 ANSWER 1 OF 6 USPATFULL on STN  
TI Novel antiangiogenic peptides, polypeptides encoding same and methods  
for inhibiting angiogenesis  
AB Mammalian kringle 5 fragments and kringle 5 fusion proteins are  
disclosed as a compounds for treating angiogenic diseases. Methods and  
compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:178957 USPATFULL  
TITLE: Novel antiangiogenic peptides, polypeptides encoding  
same and methods for inhibiting angiogenesis  
INVENTOR(S): Davidson, Donald J., Gurnee, IL, UNITED STATES  
Wang, Jieyi, Gurnee, IL, UNITED STATES  
Gubbins, Earl J., Libertyville, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040138127	A1	20040715
APPLICATION INFO.:	US 2004-753646	A1	20040108 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-924287, filed on 5 Sep 1997, GRANTED, Pat. No. US 6699838 Continuation-in-part of Ser. No. US 1997-851350, filed on 5 May 1997, GRANTED, Pat. No. US 6057122 Continuation-in-part of Ser. No. US 1997-832087, filed on 3 Apr 1997, GRANTED, Pat. No. US 5981484 Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, GRANTED, Pat. No. US 5801146		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008		
NUMBER OF CLAIMS:	68		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Page(s)		
LINE COUNT:	3457		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 6 USPATFULL on STN  
TI Antiangiogenic peptides  
AB Mammalian kringle 5 fragments and kringle 5 fusion proteins are  
disclosed as a compounds for treating angiogenic diseases. Methods and  
compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:53363 USPATFULL  
TITLE: Antiangiogenic peptides  
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States  
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States  
(U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 6699838 B1 20040302  
 APPLICATION INFO.: US 1997-924287 19970905 (8)  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-851350, filed  
 on 5 May 1997, now patented, Pat. No. US 6057122  
 Continuation-in-part of Ser. No. US 1997-832087, filed  
 on 3 Apr 1997, now patented, Pat. No. US 5981484  
 Continuation-in-part of Ser. No. US 1996-643219, filed  
 on 3 May 1996, now patented, Pat. No. US 5801146

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Low, Christopher S. F.  
 ASSISTANT EXAMINER: Robinson, Hope A.  
 LEGAL REPRESENTATIVE: Casuto, Dianne, Steele, Gregory W.  
 NUMBER OF CLAIMS: 4  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)  
 LINE COUNT: 3178  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 6 USPATFULL on STN  
 TI Antiangiogenic peptides and methods for inhibiting angiogenesis  
 AB Mammalian kringle 5 fragments are disclosed as a compounds for treating  
 angiogenic diseases. Methods and compositions for inhibiting angiogenic  
 diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2001:97890 USPATFULL  
 TITLE: Antiangiogenic peptides and methods for inhibiting  
 angiogenesis  
 INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States  
 PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251867	B1	20010626
APPLICATION INFO.:	US 1998-132154		19980811 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-132154, filed on 11 Aug 1998 And Ser. No. US 1997-832087, filed on 3 Apr 1997 Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Hendricks, Keith D.		
ASSISTANT EXAMINER:	Stole, Einar		
LEGAL REPRESENTATIVE:	Steele, Gregory W., Casuto, Dianne		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2101		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L7 ANSWER 4 OF 6 USPATFULL on STN  
 TI Antiangiogenic peptides polynucleotides encoding same and methods for  
 inhibiting angiogenesis  
 AB Mammalian kringle 5 fragments and kringle 5 fusion proteins are  
 disclosed as a compounds for treating angiogenic diseases. Methods and  
 compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2000:53906 USPATFULL

TITLE: Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis  
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States  
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6057122		20000502
APPLICATION INFO.:	US 1997-851350		19970505 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-832087, filed on 3 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Stole, Einar		
LEGAL REPRESENTATIVE:	Steele, Gregory W., Casuto, Dianne		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	3215		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L7 ANSWER 5 OF 6 USPATFULL on STN  
TI Antiangiogenic peptides and methods for inhibiting angiogenesis  
AB Mammalian kringle 5 peptide fragments are disclosed for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 1999:141891 USPATFULL  
TITLE: Antiangiogenic peptides and methods for inhibiting angiogenesis  
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States  
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981484		19991109
APPLICATION INFO.:	US 1997-832087		19970403 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Prouty, Rebecca E.		
ASSISTANT EXAMINER:	Stole, Einar		
LEGAL REPRESENTATIVE:	Steele, Gregory W., Casuto, Dianne		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2474		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L7 ANSWER 6 OF 6 USPATFULL on STN  
TI Antiangiogenic peptides and methods for inhibiting angiogenesis  
AB Mammalian kringle 5 fragments are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:132781 USPATFULL  
TITLE: Antiangiogenic peptides and methods for inhibiting angiogenesis  
INVENTOR(S): Davidson, Donald J., Gurnee, IL, United States  
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972896		19991026
APPLICATION INFO.:	US 1998-131995		19980811 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-832087, filed on 3 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Stole, Einar		
LEGAL REPRESENTATIVE:	Steele, Gregory W., Casuto, Dianne		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2444		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> e davidson, d/au  
E1 2 DAVIDSON ZACHARY LEROY/AU  
E2 1 DAVIDSON ZAHAVA/AU  
E3 0 --> DAVIDSON, D/AU  
E4 1 DAVIDSONB A M/AU  
E5 2 DAVIDSON E M/AU  
E6 1 DAVIDSONN/AU  
E7 1 DAVIDSONN S/AU  
E8 6 DAVIDSONS I/AU  
E9 1 DAVIDSONT E H/AU  
E10 98 DAVIDSSON/AU  
E11 48 DAVIDSSON A/AU  
E12 1 DAVIDSSON A A/AU

=> e wang, j/au  
E1 1 WANG ZXINGTAI/AU  
E2 2 WANG ZYX/AU  
E3 0 --> WANG, J/AU  
E4 1 WANG1 Y/AU  
E5 1 WANGA/AU  
E6 2 WANGA ALFRED/AU  
E7 1 WANGA C/AU  
E8 3 WANGA CHARLES L/AU  
E9 1 WANGA D/AU  
E10 1 WANGA D B/AU  
E11 1 WANGA G/AU  
E12 1 WANGA I/AU

=>